Hello again from Belgium. Thank you for joining us today as we report Galapagos' first quarter 2026 financial results and business update.

Last evening, we issued a press release outlining these results. This release, along with today's presentation, can be found on the Galapagos investor website at www.glpg.com.

Before we begin, I would like to remind everyone that we will be making forward-looking statements. These forward-looking statements include remarks concerning future developments of our company and our pipeline, and possible changes in the industry and competitive environment.

These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on information currently available to us and on assumptions we have made. Actual results may differ materially from those indicated by these statements and are accurate only as of the date of this recording, May 7, 2026.

Galapagos is not under any obligation to update statements regarding the future, or to conform to these statements in relation to actual results, unless required by law. You are cautioned not to place any undue reliance on these statements.

Joining us on today's call from the executive team are Henry Gosebruch, Chief Executive Officer, and Aaron Cox, Chief Financial Officer. Eric Hedrick, Chief Clinical Advisor; Sue-Ann Quan, Chief Business Officer; and Dan Grossman, Chief Strategy Officer, will be joining us for the Q&A session.

With all of that, let me now turn the call over to Henry Gosebruch, CEO. Henry?

Thank you, Sherri, and thank you all for joining us today. It is truly an exciting time to be here.

This call marks my one-year anniversary as CEO, and I couldn't be more proud of what we've accomplished together in the first year of our journey. We have transformed our management team and board, repositioned our portfolio, added an exciting set of new pipeline programs, and we are changing our name to Lakefront Biotherapeutics.

This is not a story of small adjustments. It's a story of real transformation.

A transformation like this requires the right people. At Galapagos, we've assembled a management team with world-class business development expertise and a shared mission of leveraging our unique position to develop new medicines for patients and to create significant value for our shareholders.

Our executives bring world-class deal-making experience, and each has an enviable track record. This is a team built for this new phase of our company.

We are focused on disciplined decision-making, careful capital allocation, reshaping our pipeline through business development, and focused execution that can create long-term, sustainable value. As Galapagos transforms, it's also important that the board brings the right mix of capabilities and background.

We are very pleased with the talented group that has joined us. The board's expertise and background brings the skills and experience that are needed to provide effective oversight of our strategy and the company.

Our previous board chair, Jérôme Contamine, retired from the board following the 2026 AGM/EGM. I am extraordinarily grateful for Jérôme's service.

He has been a great partner and provided valuable insights that have positioned us for this next phase of growth. I'm excited to work with Gino Santini as our new board chair going forward.

Gino is a seasoned pharmaceutical professional with a 27-year career at Eli Lilly, where he served as Senior Vice President of Corporate Strategy and Business Development and led major acquisitions and partnerships. He has advised and directed numerous pharmaceutical, biotech, and venture-backed organizations, and has relevant experience in M&A, commercial partnerships, and board governance.

Gino's extensive operational, strategic, and business development expertise, shaped by decades of global leadership in our sector, will be invaluable as we execute on our strategy to deliver meaningful patient impact and sustainable shareholder returns. Just a few weeks ago, we announced that we have entered into a binding agreement with Gilead regarding the portfolio created by Oro Medicines.

This did not happen overnight. It was the result of a structured process, early relationship building, confidential reviews, negotiations, and ultimately, successful agreement on a partnership with Gilead that has the potential to drive significant value for our shareholders.

The transaction centers on Oro's lead program, gemgurdimeg, a BCMA/CD3 T-cell engager for autoimmune diseases with multi-billion-dollar revenue potential. Currently in Phase 1b dose-ranging studies and expected to enter registrational studies as early as 2027.

Gemgurdimeg, Oro's lead molecule, is, in our view, a potential first- and best-in-class T-cell engager that has demonstrated a compelling profile in clinical studies. The collaboration brings a meaningfully clinically differentiated, high-potential asset into our portfolio.

The proof-of-concept initial indications are orphan indications where the clinical trials are manageable in size and scope, with significant potential for expansion into additional indications. Far, we've seen compelling data from over 60 patients treated with gemgurdimeg across 5 distinct autoimmune indications.

This clinical experience has highlighted the differentiated profile of gemgurdimeg, characterized by rapid induction of durable complete responses, minimal cytokine release syndrome with the current schedule of administration, and remarkable consistency in these findings across studies and disease indications. We look forward to sharing data with investors over the coming months in a series of publication and presentations at medical meetings.

We believe that gemgurdimeg has a clear speed-to-market advantage. The initial focus on the treatment of rare autoimmune diseases has provided rapid proof of concept, enabling initiation of registrational trials as early as 2027.

The program has also received Fast Track and Orphan Drug designation in the US for ITP and AIHA, further supporting an accelerated development path. Finally, the spectrum of diseases that may be addressable by gemgurdimeg encompasses over 20 separate indications, giving us a pipeline in a product opportunity.

In conclusion, we believe gemgurdimeg could represent a very important new type of treatment approach for immune reset therapy for patients across a large number of conditions. It has shown compelling clinical data so far, and it may have both a first-in-class advantage and best-in-class potential.

Our partnership also includes three exciting preclinical programs, which we will look to progress with urgency. We look forward to sharing more about these programs in the future.

Now, I'll turn the call over to Aaron to talk about financials. Aaron?

Thanks, Henry, and hello, everyone. As you heard from Henry, we are really excited about the Oro transaction.

Another major benefit is that it includes a partial waiver and modification of terms of our legacy option, license, and collaboration agreement, or OLCA, with Gilead, marking a meaningful step forward in our strategic and financial flexibility. This slide details the benefits of this transaction relative to our legacy relationship.

In short, the participation of Gilead was far above the $150 million expected with the legacy agreement. I'm really proud of our team for negotiating far better terms and proving that we are able to work together with Gilead to achieve our common goals.

As noted in our transaction announcement, under the revised terms and subject to the closing of the transaction, $500 million is now unlocked for broader use beyond the Oro investment, enabling Galapagos to pursue new opportunities and transactions independently of Gilead, and expanding the universe of potential strategic targets. Additionally, up to $150 million of this $500 million may be used for return of capital to shareholders, subject to certain limitations, providing us with additional optionality to drive shareholder value.

This partial waiver and modification to terms of the OLCA further strengthen our ability to deploy capital strategically and to pursue additional value-accretive opportunities. Along these lines, last week we also received approval from our shareholders to complete a share repurchase.

We will provide an update regarding a potential share repurchase following the close of the Oro transaction. Turning now to our Q1 2026 financial results, and as outlined in the press release issued last night, our total net revenues were €6.5 million, compared to €75 million in Q1 2025.

This decrease is mainly driven by the prior-year comparison, which included €57.6 million related to the OLCA revenue recognition. As noted with our full-year 2025 results, the remaining deferred income balance related to the OLCA was fully released at year-end 2025.

In Q1 2026, revenues were primarily driven by €4.9 million in supply revenues from Jyseleca inventory sales to Alfasigma and €1.6 million in collaboration revenues, reflecting royalties from Gilead. On the cost side, we continue to see significant reduction in our operating expenses.

R&D expenses decreased to €31 million, contributing to an overall improvement in our cost base. This reduction is driven by lower severance expenses as well as the absence of restructuring-related charges that impacted Q1 2025.

As a result, operating loss improved to €63.7 million, compared to €158.7 million last year, which included €111 million in restructuring costs. Moving below operating income, we reported net financial income of €77.7 million, mainly driven by positive fair value adjustments and favorable unrealized currency exchange gains on our US dollar-denominated cash and investments of €64.3 million.

This led to a net profit of €14.5 million for the quarter, compared to a net loss of €153.4 million for the first 3 months of 2025. Financial investments and cash and cash equivalents totaled €2,982.2 million on March 31, 2026, as compared to €3,297 million on March 31, 2025.

The quarter-end cash balance meaningfully benefited from a decrease in the US dollar to euro exchange rate, which moved from 1.175 at year-end 2025 to approximately 1.15 at the end of the quarter. Turning now to our guidance for 2026.

With the closing of the Oro transaction expected in the second quarter, we expect to spend €60 to €75 million on Oro-related cash expenditures, including operating costs and transaction expenses in 2026. Along with the upfront payment of approximately €713 million, this results in total Oro-related cash expenditures of €775 to €790 million for 2026.

We continue to expect one-time cash costs of €125 to €175 million related to the wind-down of cell therapy activities. Inclusive of the Oro-related expenditures and continued wind-down of cell therapy, we now expect to end the year with €1.975 to €2.05 billion of cash and cash equivalents.

Importantly, the company remains robustly funded. Following this transaction, and including estimated R&D spend associated with gemgurdimeg until first approval, the company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation priorities.

Now, let me turn it back to Henry to wrap up.

Thank you, Aaron. In closing, I'm just thrilled to introduce you to the new Lakefront Biotherapeutics.

To us, Lakefront symbolizes the attractive opportunity in front of us and the new beginning we are creating. My most reflective moments often occur when I'm out exercising on Chicago's lakefront.

Our new name captures what we aspire to achieve for patients: enhanced quality of life, meaningful, positive impact, and more time for what matters most. It represents helping patients move toward a better future with greater hope and possibility.

As of tomorrow, May 8th, we expect to be listed as LKFT on Euronext and Nasdaq, symbolizing another pivotal step in our transformation. With that, thank you all for your attention, and we will now open it up for your questions.

Operator?

Hey, good morning, guys. Thanks for taking my question and congrats on all the transformation over there.

I was wondering if you could give us maybe your latest thoughts on what the dose-ranging gemgurdimeg data will need to show specifically just in terms of B-cell depletion depth and durability, CRS rate reductions to move forward in registrationals, how you're going to be picking which registrational trials to begin first, and just any more thoughts on the potential size and complexity of these trials that could start next year. Thanks.

Hey, Brian. It's Henry.

Good morning. Thanks for the question.

I'll start, and then I'll have Eric supplement. Look, as we said on the prior discussion, we had a chance to really thoroughly diligence not only gemgurdimeg, but other programs out there with other T-cell engagers.

We've seen really compelling data from over 60 patients that showed very very rapid onset, very deep depletion, and very good durability. Again, as we've talked about, that will come out here in the next couple of quarters in terms of individual releases at medical meetings and other publications.

Just for context, but I'll have Eric go through the specifics on the three points you raised. Eric?

Yeah. Thanks, Henry.

Hi, Brian. Thanks for the question.

Sort of expanding on what Henry just said, I think the team at Oro has done really good work on exploring dose ranging here. I would say that the profile that would be an optimal profile for going into late-stage development would be one where you get profound B-cell depletion, but a dose-duration schedule that minimizes CRS risk.

I think at the current dose and schedule, we've referred to this previously, it really does seem like alterations in the dose and the duration of therapy can really minimize the CRS risk. I think the other aspect here that's important will be having a dose that results in a period of B-cell depletion that is deep, but relatively short, right, so that you can minimize the infectious risk, the need for supplemental intravenous immunoglobulin.

Again, I think the team at Oro is well underway to identifying that dose. We fully expect that by 2027, we'll be comfortable with the doses that we take forward into Phase 3 programs.

Yeah. Hi, guys.

Thanks for the update, and thanks for taking the question. I think we saw another transaction recently for a BCMA/CD3, and there's several assets in this space.

Just curious how you think this space might evolve and how you're thinking about development plans. Do you see room for multiple assets targeting the same mechanism within the same large indications, or do you think this is going to be an area where various assets are going to kind of carve up sub-indications, maybe stick to smaller indications as opposed to necessarily all going after the same large ones?

Thank you. Yeah.

Thanks, Judah. It's Henry.

Again, just for context, we were able to diligence multiple opportunities in some depth and were quite pleased that our top choice, i.e., gemgurdimeg, was the one that we were ultimately able to transact with. We continue to believe that gemgurdimeg is the best alternative out there and has the potential to be first in class.

That being said, look, we're very encouraged by the fact that we're not the only ones excited about this space, that there's a lot of investment going into it. I think that is good to see and ultimately good for patients.

The Oro team has been really really savvy in terms of picking very interesting indications that we believe are quite sizable, multi-billion-dollar potential easily, but where they have a clear timing advantage. I think in those places, we're in a really favorable position.

That being said, we don't view gemgurdimeg behind in any other indication as well, and those are being very actively explored. To your question whether ultimately the best drug takes all of it or the market gets split up in some way, I think we'll defer that when we go a little bit further.

Again, based on our diligence of multiple programs, we think we've got the first- and best-in-class alternative here with us. Thank you.

Good morning. Thanks for taking our questions, and congrats on the progress.

Two from us. First on gemgurdimeg, you've mentioned that it's perhaps best-in-class.

Can you go into a little bit more detail about how it is differentiated structurally or otherwise from the other BCMA/CD3s? That's first.

Then follow-on to Brian's question, in terms of moving into pivotal development, can you talk about the framework with which you're evaluating the different indications and opportunities and how you prioritize the first one or several to move forward into pivotal development? Thank you.

Eric, why don't you take the first one, and then perhaps Dan can take the second one?

Sure. Phil, thanks for your question.

I think in terms of differentiation amongst these BCMA-directed T-cell engagers, yeah, one of the things that was attractive about the Oro molecule, I guess there was two aspects. One is the de-tuning of the CD3-binding arm, which we think goes a long way in addition to dosing in significantly reducing the CRS risks, so that was important.

The BCMA-binding arm is very potent, right, and so we're comfortable that, from the data we've seen so far, is sort of resulting in very deep B-cell depletion and the sort of response in disease that you would associate with profound B-cell depletion. I think those were the main aspects of the molecule that were attractive to us.

Again, the Oro team has really advanced this very well in the clinic, and I think you're seeing the clinical representation of those molecular features. Maybe Dan, if you want to comment as well?

Yeah. Sure, I'm happy to talk about indication selection.

First, I'll echo what Henry said in terms of appreciation for the Oro team's strategic judgment in choosing initial indications in which you could get a very rapid and very clear signal of the actual clinical potency of the molecule, and particularly in the benign hematologic indications. Beyond that, we're kind of seeing gemgurdimeg as a vanguard of T-cell engager therapy for autoimmune disease broadly.

It could really be revolutionary over the next 10 years. We anticipate that in There's a high likelihood that in 10 years, it will be hard to imagine there was a time when this kind of technology was not part of standard of care across these B-cell-mediated autoimmune disease.

We are really looking for quite a bit of breadth and to get the product out into the clinic and then into the hands of physicians to see what it can do across not just different diseases, but different therapeutic areas. Of course, the first filter is always going to be a mechanistic hypothesis that deep B-cell depletion will result in meaningful clinical benefit to patients.

That's sort of effectively a proxy for PTRS. Then, within that, we see a range of disease states in which the standard of care today and anticipated over the next couple of years is woefully inadequate, there's a room to do most good for patients, where there are material-sized patient populations, and where the feasibility of running clinical trials and bringing the product to the commercial market is most feasible.

We're going to be balancing those factors, but really looking to show the broad potential of this kind of technology.

Yeah. Phil, it's Henry, just to add to Dan's answer.

One thing that, again, really attracted us in our diligence is that given how profound the impact is on patients that we've been able to see, you really need just pretty small numbers of patients in these diseases to really figure out

whether

you've got the right dosing scheme to take it forward into larger studies. We quite like the fact that this is very capital-efficient.

Again, in due time, we'll provide a little bit more on sort of our R&D spend, etc. Aaron gave it for this year, of course.

That's another very important feature, that there's really relatively modestly sized studies needed, and then you can go into pivotals, which are also quite modest given, again, this profound impact on patients we've seen.

You can do a lot with a little at this effect size.

That's very helpful. Thank you.

Hi, good morning, team. This is Yang on for Sean.

I have two questions. Maybe the first one is, could you speak to the optionality on continued BD activities and the prioritization, for instance, target or indication driven that may have a clear strategy to have a synergism with gemgurdimeg in autoimmune disease?

I have a follow-up.

Thanks for the question. It's Henry.

A couple of things. Again, we've said that the majority of our capital is available for other strategic initiatives and future BD.

Aaron walked through the $500 million bucket we now have that we can do deals independent from Gilead and where we can take a portion of that for return of capital as well. We're very excited about that flexibility and the substantial capital we have left to look for other BD.

That being said, we're very excited about Oro and the potential that we just in the prior question outlined, and the three preclinical assets we have that could also be meaningful opportunities. I would say the hurdle for the next BD deal is very, very high.

Just the hurdle for the first one was also high, but the next one is very, very high because we've got a really, really nice portfolio. We do have increased capability now, and we of course have a set of diseases that it could make sense to build on, as you say, to introduce some development or even commercial synergy down the road.

I think the message right now is, look, we're excited about what we have. We're going to be very, very busy executing these programs, and we're in no rush to do a second BD deal here given how much we have on our plate.

Great, thanks. Could you also please comment on the infection risk, hematology events associated with gemgurdimeg and all the BCMA TCE class in general, and the company's view on the differences it may be associated with CD19 TCE for autoimmune disease?

Thanks.

Eric, why don't you take that one?

Thanks for the question. I would say that, sort of in relation to the comment I made previously, the infectious risk here really has to do with the duration of B-cell depletion and plasma cell depletion, right?

When the team at Oro is giving this drug, in the current dose and schedule, we're comfortable that we're getting to the point where the period of B-cell depletion will be such that the infectious risk should be manageable. That will be a key point in sort of determining the dose to go forward.

Again, I think the key point is that you can dose this drug in such a way that you can have impact on the period of B-cell depletion, and then the infectious risk should really go along with the durability of B-cell depletion. Again, the team at Oro has done really nice job at dose ranging and trying to optimize that period.

Got it. Thanks.

Hi, yeah. Mattias coming in for Jacob.

I had a question on the Galapagos 36 667 program. What are the strategic options you're currently considering and could one of the potential outcomes be that you choose to develop the program in collaboration with Gilead, or how do you look at that program at the moment?

Thanks.

Thanks for the question. It's Henry.

As we said previously, we were analyzing various alternatives relating to 3667. That process continues, although it's quite well advanced at this point.

We're coming close to the end of that process and making a decision which way to go, and we're assessing kind of a broad range of options. More to come on that in the not-too-distant future, but it's inappropriate at this point to comment further on it.

Great. Thanks.

Very good. Thank you for your time today.

We look forward to closing the Oro transaction here in the second quarter and welcoming the team from Oro to join us here. More broadly, reflecting on the last year, it's just really been a fantastic year, and I'm super proud of what we've accomplished together.

I'm also super excited about the year ahead for Lakefront Bio. Thank you, and we hope you have a great day.